Roche Spin-Off Nimble Therapeutics to Commercialize its Drug Development Technology
Roche’s Tecentriq + Bevacizumab Receive Health Canada’s Approval as 1L Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
Shots:
- Nimble Therapeutics spins out from Roche to commercialize its chemical synthesis drug discovery & development technology and has received $10M Series A funding from Telegraph Hill Partners
- The focus of spinning out Nimble Therapeutics is to expand Roche’s chemical synthesis technology by collaborating with other pharma companies to jointly develop drug candidates for multiple therapeutic areas
- The chemical synthesis technology harnesses the power of photolithography and an extensive library of photoprotected amino acids for synthesis & screening of peptides including scaffolded natural and modified macrocyclic peptidomimetics
Click here to read full press release/ article | Ref: Nimble Therapeutics | Image: Video Blocks